CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: April 29, 2021
Result type: Reports
Project Number: SR0691-000
Product Line: Reimbursement Review

Generic Name: colchicine

Brand Name: Myinfla

Manufacturer: Pendopharm, a division of Pharmascience Inc.

Therapeutic Area: Atherothrombotic events in coronary artery disease

Indications: ​Reduction of atherothrombotic events in patients with existing coronary artery disease.

Manufacturer Requested Reimbursement Criteria1: ​For prevention of cardiovascular events in patients after myocardial infarction and who are treated according to the national guidelines (standard of care).

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: April 29, 2021

Call for patient/clinician input closed: June 18, 2021

Anticipated Date: May 28, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback